Week of January 4th 2022 | Vol. 11, Issue 1
In This Issue
Upcoming Events
Industry M&A Activity
  • Recent Transactions
  • Trading Comps
  • Market Reports
  • M&A Pipeline
Featured Headlines
Tanner Updates

Quick Links

Contact Information
Managing Director
Business Development

Managing Director
Head of M&A and Capital Advisory
Industry Snapshot
Above is an overview of recent industry M&A activity. Click on the chart to download complete transaction tables broken out by industry sub sectors. For additional information, see the Industry M&A Activity section below.
Events Hosted or Attended by Bourne Partners
Dates TBD - Charlotte, NC

January 10-13, 2022 - Attending Virtually
INDUSTRY M&A ACTIVITY
Recent Transactions, Trading Comps, Market Reports, M&A Pipeline
RECENT TRANSACTIONS
An Overview of Transactions Within Market Sub-segments
Below are summaries and charts with the past week's transactions from the different healthcare sectors. For a detailed table showing data for each industry transaction click on any of the charts. Total transaction values are provided in USD millions.
M&A TRANSACTIONS
Pharma & Biotech
6 transactions totaling $353 million

Supplies, Equipment & Services
10 transactions totaling $160 million

Healthcare IT & Managed Care
1 transaction

Healthcare Facilities & Distributors
2 transactions totaling $198 million
PRIVATE PLACEMENTS
Pharma & Biotech
14 transactions totaling $298 million

Supplies, Equipment & Services
14 transactions totaling $598 million

Healthcare IT & Managed Care
9 transactions totaling $20 million

Healthcare Facilities & Distributors
0 transactions
PUBLIC OFFERINGS
Pharma & Biotech
3 transactions totaling $256 million

Supplies, Equipment & Services
5 transactions totaling $900 million

Healthcare IT & Managed Care
0 transactions

Healthcare Facilities & Distributors
0 transactions
TRADING COMPS
A Breakdown of Relevant Trading Multiples
This is a high-level breakdown of median revenue and EBITDA multiples for each of the specific sub sectors.

For a complete trading comp analysis (including the individual equities that comprise the sub sectors), click on the table. 

Note: data reflects prior week close.
MARKET REPORTS
Insight Into Healthcare Related Industries
M&A PIPELINE
Representative Current Retained Sell-Side And Partnering Opportunities
Project Alamo
Sell-side | CMO | Corporate Carve out - private label and OTC manufacturing business

Project Focus
Sell-side | CMO | Liquids and Semi-solids CMO headquartered in North America

Project Nucleus
Buy-side| CDMO | North American radiopharmaceutical company
Project Power Play
Buy-side | Specialty Pharma | In-license and acquire approved Rx products including legacy brands, generics, and niche launch-ready products

Project Trident
Buy-side | Generic Pharma | Manufacturing liquid generics
FEATURED HEADLINES
A Sampling of Industry Headlines From Last Week
Oracle is buying electronic medical records firm Cerner in a deal valued at $28.3 billion, one of the software company’s biggest acquisitions ever and one of the largest takeovers this year. 

The all-cash deal values Cerner at $95 a share and was announced Monday just three days after rumors circulated that Oracle was in talks to buy the health IT company.

The acquisition will be immediately accretive to Oracle's earnings on a non-GAAP basis in the first full fiscal year after closing—and will contribute substantially more to earnings in the second fiscal year, according to Safra Catz, Oracle's Chief Executive Officer.

Oracle also plans to expand Cerner's business into more international markets.
Gyroscope Therapeutics has been spun this way and that in 2021, going from a $148 million raise to a failed IPO to a $40 million investment from Sanofi in quick succession. But Novartis has ensured the gene therapy startup has ended the year at the top of its arc by inking a $1.5 billion buyout. 
Curebase, which is focused on siteless clinical trials, has joined the WCG Avoca Quality Consortium that boasts more than 175 pharma, biotech, clinical site and CRO organizations. In the consortium, which was founded in 2011, members work together to improve clinical trial quality by staying on top of challenges facing the industry, the group said.
Senti Biosciences is hopping on the SPAC track with a deal that will provide $296 million in proceeds for the preclinical biotech to move its gene circuit engineered cell and gene therapies toward human trials. South San Francisco-based Senti will tie up with special purpose acquisition company (SPAC) Dynamics Special Purpose, according to a Monday release. 
Mental health startup Cerebral has inked a partnership with Alto Neuroscience to bring clinical trials for depression to patients’ homes. Through the collaboration, Cerebral is able to offer its network of members the opportunity to participate in at-home clinical research utilizing Alto’s biomarker platform and targeted drug candidates. 
We are looking for pharma professionals to join our expanding US and UK teams.